The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis

Vaccine

Volumn 34, Issue 13, 2016, Pages 1540-1550

  Kraicer Melamed, Hannah ^a,b   O'Donnell, Shauna ^a,b   Quach, Caroline ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

23 Valent pneumococcal polysaccharide vaccine; Effectiveness; Elderly; Systematic review, Meta analysis

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

ADULT; AGE; AGED; ALASKA NATIVE; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MANDATORY REPORTING; META ANALYSIS; MORTALITY RATE; NICARAGUA; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PUBLISHING; QUALITY CONTROL; SEROTYPE; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; VACCINATION; COMMUNITY-ACQUIRED INFECTIONS; MEASUREMENT ACCURACY; MICROBIOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, BACTERIAL;

AGED; COMMUNITY-ACQUIRED INFECTIONS; DATA ACCURACY; HUMANS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL;

EID: 84960362899     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.024     Document Type: Article

References (56)

1. Global Burden of Disease Collaborators Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 2015, 386:2145-2191.
2. Bonten M.J., Huijts S.M., Bolkenbaas M., Webber C., Patterson S., Gault S., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015, 372:1114-1125.
3. Evidence-based recommendations for immunization - methods of the National Advisory Committee on Immunization. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2009, 35:1-10. National Advisory Committee on Immunization.
4. Harris R.P., Helfand M., Woolf S.H., Lohr K.N., Mulrow C.D., Teutsch S.M., et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prevent Med 2001, 20:21-35.
5. Broome C.V., Facklam R.R., Fraser D.W. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980, 303:549-552.
6. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
7. National Advisory Committee on Immunization Re-Immunization with Polysaccharide 23-Valent Pneumococcal Vaccine (Pneu-P-23) 2015.
8. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
9. StataCorp. Stata statistical software: release 13 2013, StataCorp LP, College Station, TX.
10. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62:1006-1012. PRISMA Group.
11. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
12. Tsai Y.H., Hsieh M.J., Chang C.J., Wen Y.W., Hu H.C., Chao Y.N., et al. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old-Taiwan's PPV vaccination program. Vaccine 2015, 33:2897-2902.
13. Singleton R.J., Butler J.C., Bulkow L.R., Hurlburt D., O'Brien K.L., Doan W., et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine 2007, 25:2288-2295.
14. Loeb M., Neupane B., Walter S.D., Hanning R., Carusone S.C., Lewis D., et al. Environmental risk factors for community-acquired pneumonia hospitalization in older adults. J Am Geriat Soc 2009, 57:1036-1040.
15. Farrington C.P. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 1993, 22:742-746.
16. Andrews R.M., Counahan M.L., Hogg G.G., McIntyre P.B. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine 2004, 23:132-138.
17. Gutierrez Rodriguez M.A., Ordobas Gavin M.A., Garcia-Comas L., Sanz Moreno J.C., Cordoba Deorador E., Lasheras Carbajo M.D., et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the region of Madrid, Spain, 2008-2011. Eurosurveill 2014, 19:1-9.
18. Mooney J.D., Weir A., McMenamin J., Ritchie L.D., Macfarlane T.V., Simpson C.R., et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis 2008, 8:53.
19. Rudnick W., Liu Z., Shigayeva A., Low D.E., Green K., Plevneshi A., et al. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. Vaccine 2013, 31:5863-5871.
20. Wright L.B., Hughes G.J., Chapman K.E., Gorton R., Wilson D. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in people aged 65 years and over in the North East of England, April 2006-July 2012. Trials Vaccinol 2013, 2:45-48.
21. Menzies R.I., Krause V.L., McIntyre P.B. Impact of pneumococcal polysaccharide vaccine in people aged 65 years or older. Med J Austr 2014, 201:200.
22. Hanna J.N., Humphreys J.L., Murphy D.M., Smith H.V. Invasive pneumococcal disease in non-Indigenous people in north Queensland, 2001-2009. Med J Austr 2010, 193:392-396.
23. Becker-Dreps S., Amaya E., Liu L., Rocha J., Briceno R., Moreno G., et al. Impact of a combined pediatric and adult pneumococcal immunization program on adult pneumonia incidence and mortality in Nicaragua. Vaccine 2015, 33:222-227.
24. Vila-Corcoles A., Ochoa-Gondar O., Hospital I., Ansa X., Vilanova A., Rodriguez T., et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: The EVAN-65 Study. Clin Infect Dis 2006, 43:860-868.
25. Andrews N.J., Waight P.A., George R.C., Slack M.P.E., Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012, 30:6802-6808.
26. Dominguez A., Salleras L., Fedson D.S., Izquierdo C., Ruiz L., Ciruela P., et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis 2005, 40:1250-1257.
27. Vila-Corcoles A., Ochoa-Gondar O., Guzman J.A., Rodriguez-Blanco T., Salsench E., Fuentes C.M. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect Dis 2010, 10.
28. Honkanen P.O., Keistinen T., Miettinen L., Herva E., Sankilampi U., Laara E., et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999, 17:2493-2500.
29. Ortqvist A., Hedlund J., Burman L.A., Elbel N., Hofer M., Leinonen M., et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998, 351:399-403.
30. Christenson B., Pauksen K., Sylvan S.P. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J 2008, 5:52.
31. Vila-Corcoles A., Salsench E., Rodriguez-Blanco T., Ochoa-Gondar O., de Diego C., Valdivieso A., et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 2009, 27:1504-1510.
32. Ochoa-Gondar O., Vila-Corcoles A., Rodriguez-Blanco T., Gomez-Bertomeu F., Figuerola-Massana E., Raga-Luria X., et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014, 58:909-917.
33. Wiemken T.L., Carrico R.M., Klein S.L., Jonsson C.B., Peyrani P., Kelley R.R., et al. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study. Vaccine 2014, 32:2198-2203.
34. Christenson B., Hedlund J., Lundbergh P., Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004, 23:363-368.
35. Ansaldi F., Turello V., Lai P., Batone G., De Luca S., Rosselli R., et al. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study. J Int Med Res 2005, 33:490-500.
36. Kawakami K., Ohkusa Y., Kuroki R., Tanaka T., Koyama K., Harada Y., et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 2010, 28:7063-7069.
37. Jackson L.A., Neuzil K.M., Yu O., Benson P., Barlow W.E., Adams A.L., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348:1747-1755.
38. Jackson M.L., Nelson J.C., Jackson L.A. Risk factors for community-acquired pneumonia in immunocompetent seniors. J Am Geriatr Soc 2009, 57:882-888.
39. Skull S.A., Andrews R.M., Byrnes G.B., Kelly H.A., Nolan T.M., Brown G.V., et al. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine 2007, 25:4631-4640.
40. Song J.Y., Lee J.S., Wie S.H., Kim H.Y., Lee J., Seo Y.B., et al. Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization. Clin Vacc Immunol 2015, 22:229-234.
41. Moberley S., Holden J., Tatham David P., Andrews Ross M. Vaccines for preventing pneumococcal infection in adults. Cochrane database of systematic reviews 2013, John Wiley & Sons, Ltd.
42. Jain S., Self W.H., Wunderink R.G., Fakhran S., Balk R., Bramley A.M., et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015, 373:415-427.
43. Johnstone J., Marrie T.J., Eurich D.T., Majumdar S.R. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007, 167:1938-1943.
44. Feikin D.R., Kagucia E.W., Loo J.D., Link-Gelles R., Puhan M.A., Cherian T., et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013, 10:e1001517-e1001520.
45. Conaty S., Watson L., Dinnes J., Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004, 22:3214-3224.
46. Watson L., Conaty S., Dinnes J., Waugh N. Comparing systematic reviews of RCTs and observational studies: the case of pneumococcal polysaccharide vaccine [abstract]. XI Cochrane colloquium: evidence, health care and culture; 2003 Oct 26-31 2003, p. 41.
47. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ Can Med Assoc J 2009, 180:48-58. [Erratum appears in CMAJ 2009;180(10):1038].
48. Hutchison B.G., Oxman A.D., Shannon H.S., Lloyd S., Altmayer C.A., Thomas K. Clinical effectiveness of pneumococcal vaccine - meta-analysis. Can Fam Physician 1999, 45:2381-2393.
49. Melegaro A., Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004, 19:353-363.
50. Cornu C., Yzebe D., Leophonte P., Gaillat J., Boissel J.P., Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001, 19:4780-4790.
51. Moore R.A., Wiffen P.J., Lipsky B.A. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000, 1:1.
52. Fedson D.S. Preventing non bacteremic pneumococcal pneumonia in older adults: Historical background and considerations for choosing between PCV13 and PPV23. Hum Vacc Immunotherap 2014, 10:1322-1330.
53. Leventer-Roberts M., Feldman B.S., Brufman I., Cohen-Stavi C.J., Hoshen M., Balicer R.D. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged 65+: a retrospective case-control study. Clin Infect Dis 2015, 60:1472-1480.
54. Elston J.W., Santaniello-Newton A., Meigh J.A., Harmer D., Allgar V., Allison T., et al. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK 2002-2009. Epidemiol Infect 2012, 140:1252-1266.
55. Hechter R.C., Chao C., Jacobsen S.J., Quinn V.P., Van Den Eeden S.K., et al. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study. Vaccine 2012, 30:5625-5630.
56. Dominguez A., Izquierdo C., Salleras L., Ruiz L., Sousa C., Bayas J.M., et al. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Respir J 2010, 36:608-614.